Replies to post #458184 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Absolutely true! We all know there is no way NWBO would have been permitted to continue to treat patients with a failed therapy, nor would they have wanted to do so!

Why??? It is common for drugs to fail in a trial and continue to be studied in other trials.

PPHM's Bavituximab's trial for NSCLC was halted for futility and continued to treat patients.

CVM's Multikine had a futility rec and decided to carry on. The FDA partial hold allowed patients already enrolled to continue treatment but no new enrollments. When CVM agreed to not enroll more patients the hold was lifted.

DNDN's Provenge failed 2 pivatol P2s yet the IMPACT trial in progress was allowed to continue and generate an approval.

Hercepten failed a key early trial and is a blockbuster.

Erbitux had a huge early fail with the FDA, yet went on to success (though not for Sam and Martha).